bapotulimab + pembrolizumab

Bapotulimab (BAY1905254) is an investigational monoclonal antibody developed by Bayer. It is being studied in combination with pembrolizumab for the treatment of advanced solid tumors and recurrent or metastatic head and neck squamous cell carcinoma expressing PD-L1. Pembrolizumab is a humanized IgG4-kappa monoclonal antibody marketed as Keytruda by Merck & Co. It acts as an immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), thereby blocking its interaction with PD-L1 and PD-L2 to enhance anti-tumor immune responses. The combination aims to improve tumor response rates by leveraging dual immunomodulatory mechanisms[1][3][7].